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Abstract
Because cytotoxic T-lymphocytes (CTLs) have been shown to play a role in controlling human immunodeficiency virus (HIV)
infection and because CTL-based simian immunodeficiency virus (SIV) vaccines have proved effective in non-human
primates, one goal of HIV vaccine design is to elicit effective CTL responses in humans. Such a vaccine could improve viral
control in patients who later become infected, thereby reducing onwards transmission and enhancing life expectancy in the
absence of treatment. The ability of HIV to evolve mutations that evade CTLs and the ability of these ‘escape mutants’ to
spread amongst the population poses a challenge to the development of an effective and robust vaccine. We present a
mathematical model of within-host evolution and between-host transmission of CTL escape mutants amongst a population
receiving a vaccine that elicits CTL responses to multiple epitopes. Within-host evolution at each epitope is represented by
the outgrowth of escape mutants in hosts who restrict the epitope and their reversion in hosts who do not restrict the
epitope. We use this model to investigate how the evolution and spread of escape mutants could affect the impact of a
vaccine. We show that in the absence of escape, such a vaccine could markedly reduce the prevalence of both infection and
disease in the population. However the impact of such a vaccine could be significantly abated by CTL escape mutants,
especially if their selection in hosts who restrict the epitope is rapid and their reversion in hosts who do not restrict the
epitope is slow. We also use the model to address whether a vaccine should span a broad or narrow range of CTL epitopes
and target epitopes restricted by rare or common HLA types. We discuss the implications and limitations of our findings.
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Introduction
The development of a HIV vaccine is one of the key global
health priorities of our time. Early vaccine candidates aimed to
elicit antibodies but conclusively failed in their goal of providing
sterilising immunity [1]. It is now clear that many challenges exist
in engendering effective antibodies [2,3]. It is also now apparent
that immune cells called cytotoxic t-lymphocytes (CTLs) play an
important role in controlling viral replication during natural HIV
infection [4–8] and that eliciting these responses – alone or
alongside antibodies – may be key to vaccination success.
Because CTLs target infected cells rather than free virus a
vaccine that induces only CTL responses would be unlikely to
provide sterilizing immunity; instead a realistic aim is for such a
vaccine is to contain the virus at levels that are low enough to
prevent onwards transmission and slow the onset of AIDS.
Successful trials of CTL-based SIV and SHIV vaccines in non-
human primates provide hope that this may one day be an
achievable goal [9–13]. Notably, Hansen at al. recently demon-
strated that CTLs were responsible for markedly reducing viral
replication in macaques experimentally infected with a highly
pathogenic strain of SIV [12]. However, the success that has been
had in macaques has not yet been translated to humans. The only
large scale human trial of an HIV vaccine specifically designed to
elicit CTLs was not successful [14]. Not only did the MRKAd5
vaccine fail (as anticipated) to prevent infection, it also failed in its
main objective of reducing viral replication in those who became
infected.
The only positive news from large scale human vaccine trials
has recently come from a Thai study in which high risk individuals
were inoculated with a combination of two immunogens – one
intended to induce antibodies, the other to induce CTLs [15]. This
combined approach was reported to reduce infection probability
by 31% over a 3 years study period. The result, however, was
borderline significant, appeared to wane over time and was
scrutinised over the inclusion of certain individuals in the statistics
[16]. Furthermore, the immunological analysis is pending, thus a
number of questions remain about this study including the nature
of any protective immune responses, the reasons for their demise
and the ability to reproduce and improve upon this result in future
trials. The precise makeup of an effective vaccine therefore
remains unclear and current trials continue to explore the capacity
of both the humoral and cellular arms of the immune system
(www.iavi.org).
One of the challenges of vaccine research lies in HIV’s ability to
evolve mutant strains that evade immune responses [6,7,17].
These ‘escape mutants’ pose a particular type of problem to the
development of a CTL-based vaccine that, as prototyped in
macaques [12], could suppress viral replication in infected hosts,
but not prevent infection. Under such a vaccination scenario, CTL
escape mutants could be generated within vaccinated hosts
[18,19], transmitted between hosts [20,21] and accumulate at
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how CTL escape mutants will evolve in a vaccinated population,
what effect they will have on the impact of a vaccine, and how
vaccines should be designed to reduce their impact.
Several factors, in addition to the rate at which mutants are
selected, arelikely to influencethe evolution of CTL escapemutants
and the impactof a CTL-based vaccine at the populationlevel.One
considerationisthe hugelevelofdiversityamongstthepopulationin
the genes that encode the human leukocyte antigen (HLA). HLA
class I genes determine the epitopes (antigenic sections of viral
protein) to which each individual can make CTL responses. This
means that different hosts make responses to (or ‘restrict’) different
epitopes. Whilst vaccination will not be able to change the epitopes
that each individual can restrict, it is hoped that it will be able to
improve the responses to those epitopes they do restrict, and make
them come into play earlier on during infection. As different hosts
restrict different epitopes they also drive the evolution of different
escape mutants and a mutation that is advantageous to the virus
in one individual will not necessarily be advantageous when
transmitted to another. Furthermore, because mutations can
impose a fitness cost on the virus [25,26] reversion of escape
mutations can occur following transmission to a new host [27,28].
The spread of escape mutants at the population level is therefore
also likely to be influenced by reversion rates and the frequencies of
different HLA types in the population.
Another factor that could affect the impact of a vaccine is the
breadth of the CTL response that the vaccine elicits. HLA
diversity means that any vaccine capable of providing protection
throughout a population would have to encode protein that spans
a range of different CTL epitopes restricted by different HLA-
alleles. A broader range of epitopes would not only satisfy different
HLA-restrictions, but might also be more robust in the event of
escape.
In this study we investigate how CTL escape mutations are
likely to evolve in a vaccinated population and how CTL escape
could affect the impact of an HIV vaccine. Specifically, we ask the
following four questions:
N How would a CTL-inducing vaccine affect the progression of
an HIV-epidemic?
N How would selection, reversion and transmission of CTL
escape mutants affect the impact of a vaccine?
N Should a vaccine span a broad or narrow range of CTL
epitopes?
N Should a vaccine target epitopes restricted by rare or common
HLA alleles?
To address these questions we have created a simple mathe-
matical model that describes a population receiving a vaccine
which induces CTL responses to multiple epitopes. Crucially, the
model includes within-host evolution and between-host transmis-
sion of viral variants that have escaped from CTL responses. It is a
natural extension of a model that we previously developed to
investigate the evolution and spread of CTL escape mutants in an
unvaccinated population [22].
Results
Modelling the spread of escape mutants in a vaccinated
population
The model that we have developed represents the dynamics of
escape in a population that receives a vaccine that induces CTL
responses. It is assumed that the vaccine can confer better viral
control, resulting in an enhanced life expectancy and a reduction
of infectiousness. For simplicity we focus this study on modelling
a wholly CTL-based vaccine that does not provide sterilizing
immunity, i.e. does not prevent infection in vaccinated hosts.
However, there is flexibility in the model to consider a vaccine that
also provides a degree of sterilizing immunity and we comment on
such model results later. The vaccine induces CTL responses to
multiple epitopes and to represent host heterogeneity in HLA
types, each epitope can be recognised by only a fraction of the
population. To represent viral diversity there are different strains
of the virus such that at each epitope the virus can take the
wildtype or escape mutant form. For simplicity, there are no mixed
infections, or more precisely, each host can only be infectious with
one strain at any given time. A strength of this model is that it
captures events whilst viruses evolve within individuals and tracks
the spread of variants as viruses are transmitted between
individuals. An individual who is infected with a virus that is the
wild-type form at an epitope that their HLA can restrict can
mount an effective CTL response to that epitope. Such an
individual can drive the evolution of an escape mutant at that
epitope and can therefore switch to becoming infected with a
strain that has the escape mutant at that epitope. A host who is
HLA mismatched for a particular epitope is unable to mount a
CTL response to that epitope, irrespective of vaccination and the
mutations it bears at that epitope, thus their infecting virus can
revert from an escape mutant to the wild-type strain at that
epitope. The rate of reversion is the same in both vaccinated and
unvaccinated hosts.
In this model the presence of CTL escape mutations affects the
effectiveness of the vaccine. The enhancement to life expectancy
and reduction in infectiousness conferred by the vaccine only
applies to hosts who are infected with virus that is wildtype at at
least one of the vaccine epitopes for which they are HLA-matched.
Each epitope is assumed to act independently. Thus, each
response is either beneficial or neutral to viral control, the impact
of a vaccine is independent of which epitopes there are responses to
and escape rates at each epitope are independent of both the
presence of escape mutants at other epitopes and the contribution
that other epitopes make to viral control. Between-host transmis-
sion is modelled using a standard mathematical description of the
frequency-dependent transmission of an infectious disease from
which there is no recovery [29]. Every infected host is infectious
with the viral type they carry, so that the different viral types are
transmitted between individuals at rates driven by the propor-
tion of the total population infected with each. A mathematical
Author Summary
The evolution and spread of HIV strains that evade
the immune response poses a major challenge to the
development of an effective and robust HIV vaccine. We
present a new mathematical tool that we use to dissect
the drivers of the spread of these ‘immune escape
mutants’ in a vaccinated population. Our study focuses
on a vaccine that can reduce infectiousness and enhance
longevity but does not provide sterilizing immunity. We
show that in the absence of escape such a vaccine could
reduce the prevalence of both infection and disease in the
population. However, vaccine impact could be significantly
abated by immune escape mutants, especially if they
emerge rapidly and revert very slowly after transmission to
hosts in whom the original selection pressure is absent. We
also discuss the effect that vaccine breadth and the
frequency with which different epitopes are targeted have
upon vaccine impact.
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prescribing the model (Equation 1), are provided in the methods
section. A description of model variables (Table 1), model
parameters (Table 2) and additional terms used to enable the
model equations to be written in a simple and general form
(Table 3) are also provided. Finally, a schematic diagram of the
model for the special case where the vaccine contains only a single
epitope is shown in Figure 1.
We have used the model to simulate the application of a vaccine
to all hosts in a population 50 years into an epidemic and to all
newborns thereafter (c~1). The vaccine is assumed to be effective
only in hosts who are not infected at the time of vaccination. As
the main purpose of this study is to explore the underlying factors
that drive the effectiveness of vaccination we have deliberately kept
application of this model as simple as possible. Because of
computational limitations, one of the main simplifications that we
make in our simulations is that the vaccine can elicits responses to
only five CTL epitopes (n~5). Given the huge variability in HLA
types amongst the population, each epitope has the potential to be
recognised by only a small fraction of the population, thus any
vaccine will have to elicit a much broader response than modelled
here if it is to provide robust protection to the majority of
individuals. Because it is not computationally feasible to increase
the modelled vaccine breadth further, we have attempted to
maximise vaccine coverage by assuming that all hosts receive the
vaccine (c~1) and that a large fraction (20%) of hosts are HLA
matched for each epitope. In reality, HLA prevalences below 10%
[30] and a vaccine coverage below 80% would be more typical
[31]. To restrict unrealistic rapid spread of escape at each epitope,
we did not increase the restricting HLA prevalence at each epitope
any further. Recognition of each epitope is assumed to be
independent (p11000~0:22|0:83~0:02), meaning that the pro-
portion of hosts restricting each number of epitopes (0 to 5) is
described by a binomial (5,0.2) distribution: 33% recognise no
epitopes, 41% recognise one epitope, 20% recognise two epitopes
and 6% recognise three or more epitopes. The median number of
epitopes recognised is therefore only one, much lower than
expected in reality (at least seven epitopes [32]), meaning that our
simulations likely provide conservative estimates of the impact of
vaccination.
Whereas we explicitly model only a limited number of vaccine
epitopes, an implicit assumption of this model is that all hosts make
natural responses to (perhaps many) more epitopes than just those
included in the vaccine. Thus, whilst we assume that vaccine-
driven responses to unmutated epitopes included in the vaccine
can enhance life expectancy, natural responses to unmutated
epitopes included in the vaccine are assumed to have no impact
upon life expectancy. In reality, escape mutants may affect the life
expectancy of unvaccinated hosts; however, we make this
assumption because we are most interested in the effect of escape
mutants upon vaccine impact, rather than their impact upon life
expectancy in natural infection.
Another simplification of our approach pertains to the epidemic
dynamics (i.e. infection prevalence over time) borne out by our
simple model. We loosely base our simulations upon an epidemic
in a high risk southern African population assuming that the basic
reproductive number (R0) in the absence of vaccination is equal to
2, as recently estimated from a population in Zambia [33]. This
epidemiological metric defines the average number of secondary
cases caused by one primary case in a wholly susceptible
population. However, even using an R0 tailored to Zambia does
not fully reproduce the epidemics dynamics observed in that
population, where infection prevalence appears to have stabilised
at around 15% (lower than the equilibrium prevalence of 50%
achieved with an R0 of 2), despite a continual increase in infected
numbers coupled with marked population growth. Various factors
could contribute to this discrepancy including heterogeneity of risk
across individuals. Nevertheless, we use this simplified represen-
tation of transmission for reasons of transparency, analytical
tractability and consistency with other modelling approaches
[22,29]. Accordingly, the broad dynamics indicated by this study
should be regarded as more meaningful than the precise numerical
findings. We leave more detailed tailoring of vaccine models to
specific populations for future studies.
How would a CTL-inducing vaccine affect the
progression of an HIV epidemic?
Using this model we have considered the impact that
vaccination would have on the proportion of hosts in the
population infected with HIV (HIV prevalence) and on the
proportion of hosts with uncontrolled HIV infections. Here
‘uncontrolled infections’ represent all infections except those in
which the host is vaccinated and escape mutations have not
rendered the vaccine useless. Thus, only hosts with uncontrolled
HIV have the potential to progress to AIDS. Vaccination is
assumed to be successful (i.e. control infection) in a particular host
Table 1. A description of variables used to describe our model.
Symbol Description
t Time
i Epitope number (from 1 to n)
h~(h1,h2,:::,hn) Host type, indicating which of the n epitopes the host restricts: hi~1 if the host restricts epitope i and hi~0 if it does not.
v~(v1,v2,:::,vn) Virus type, indicating the epitopes at which the virus carries escape mutants: vi~1 if the virus is mutant at epitope i and vi~0 if it is wildtype.
Rh(t) The number of vaccinated resistant hosts of type h at time t
Xh(t) The number of unvaccinated susceptible hosts of type h at time t
~ X Xh(t) The number of vaccinated susceptible hosts of type h at time t
Yh
v (t) The number of unvaccinated type h hosts infected with virus type v at time t.
~ Y Yh
v (t) The number of vaccinated type h hosts infected with virus type v at time t.
N(t) The total number of hosts in the population at time t.
lv(t) Force of infection from infected hosts with virus type v at time t.
doi:10.1371/journal.pcbi.1002289.t001
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restricts and in which that host’s infecting virus does not have
escape. This is illustrated in Text S1. Successful vaccination
confers a longer life expectancy and a reduction in infectiousness
compared to other infected individuals.
To model the spread of escape mutants amongst the population,
we have assumed that escape takes an average of 8 years post
infection at each epitope in both vaccinated (~ w wi~1=8years
21 for
i=1:5) and unvaccinated (wi~1=8years
21 for i=1:5) HLA
matched hosts [22]. At each epitope, reversion in HLA mis-
matched hosts is assumed to take an average of 36 years post
infection (yi~1=36 years
21 for i=1:5) [22]. We further explore
these parameter choices in the next section.
Our model predicts that even a vaccine that does not prevent
hosts from becoming infected could have an impact upon an HIV
epidemic. The proportion of people with uncontrolled infections
could be reduced by vaccination (Figure 2A) since many people
who become infected would stem the normal progression of the
infection towards disease, at least temporarily, because of the
protection offered by the vaccine. The proportion of people
infected with HIV could also be reduced (Figure 2B, circles) since
hosts who are protected by a vaccine would be less infectious
compared to unvaccinated hosts (~ b bvb). These basic dynamics are
reproduced under different assumptions about the underlying
epidemic, however the numerical results differ. This is demon-
strated in Figure S1 by considering epidemics parameterised by
different basic reproductive numbers.
Precisely whether or not a vaccine has a positive impact upon
the proportion of the population infected, however, also depends
upon the extent to which successful vaccination extends life
expectancy and thus extends the period over which hosts can
transmit. To demonstrate this, we introduce the concept of the
Table 2. Definitions of the model parameters and a description of the parameter values used in our simulations.
Symbol Description Value used in simulation Interpretation of parameter
m Population death rate 1/50 years
21 Uninfected hosts have an average life expectancy of 50 years.
This estimateis based upona population inSouthernAfrica [36].
B Population birth rate m
P
h
Xh(0) The population size is constant in the absence of infection.
c Proportion of newborns
who receive the
vaccine at birth.
0 for the first 50 years of the epidemic and
1b e y o n dy e a r5 0 .
No hosts receive the vaccine between years 0 and 50. Beyond
year 50 all newborns receive the vaccine. Note that in addition
wehave assumed that all other hosts receive the vaccine at year
50.
ph Proportion of hosts in
the population with
host type h











is the number of epitopes for which the host is HLA




Recognition of each epitope is assumed to be independent. In
Figure 7 different percentages of the population recognising
each epitope are considered: 10%, 30% and 50%. In the
remaining figures 20% of the population recognise each
epitope.
wi Rate of escape at epitope
i in unvaccinated HLA
matched hosts.
In Figure 3 different escape rates (the same rate at
each epitope) are compared: 1/3 years
21,1 / 3 0y e a r s
21
and 0 years
21. In Figure 5 rates ranging from 0 years
21
to 1/1000 years
21 are considered. In the remaining
figures the rate at each epitope is 1/8 years
21 [22].
The reciprocal of the rate of escape is equal to the average time
between infection and escape.
~ w wi Rate of escape at epitope i in
vaccinated HLA matched hosts.
~ w wi~wi At each epitope escape occurs at the same rate in vaccinated
and unvaccinated hosts.
yi Rate of reversion at epitope
i in HLA mismatched hosts.
In Figure 4 different reversion rates (the same at
each epitope) are compared: 1/3 years
21,1 / 3 0y e a r s
21
and 0 years
21. In Figure 5 rates ranging from 0 years
21
to 1/1000 years
21 are considered. In the remaining
figures the rate at each epitope is 1/36 years
21 [22].
The reciprocal of the rate of reversion is equal to the average
time between infection and reversion.
a Disease-related death rate of
unvaccinated or unsuccessfully
vaccinated hosts
(1/10-m)y e a r s
21 The average life expectancy in the absence of vaccine-induced
protection (1/(m+a)) is 10 years [37]. This estimate assumes that
infected unvaccinated hosts do not receive treatment.
~ a a Disease-related death rate of
successfully vaccinated hosts.
0 years
21 Successfully vaccinated hosts have the same life expectancy as
uninfected hosts.
b Transmission rate per partnership
with an unvaccinated or
unsuccessfully vaccinated host
0.2/c In an unvaccinated population this yields a basic reproduction
number of 2 [33].
~ b b Transmission rate per partnership
with a successfully vaccinated
hosts.
In Figure 2 different values are considered: 0.008/c
and 0.1/c. In the remaining figures: 0.008/c
In Figure 2 successfully vaccinated hosts are 25 times or 2 times
less infectious compared to unvaccinated or unsuccessfully
vaccinated hosts. In the remaining figures they are 25 times less
infectious.
c Rate of partner exchange See above See above.
r Fraction of vaccinated hosts
resistant to infection
0 No hosts are resistant to infection
n Number of epitopes in the
vaccine
In Figure 6 different number of epitopes are considered:
1, 3 and 5. In the remaining simulations there are
5 epitopes.
This is the number of epitopes that the vaccine is capable of
inducing CTL responses to.
doi:10.1371/journal.pcbi.1002289.t002
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coefficient (bc) of the host and the average life expectancy of the
host (1=(mza)). This value, which we denote L, differs depending
upon whether the host is successfully vaccinated or unvaccinated –
a term we use here to describe hosts who have either not received
the vaccine or who are unsuccessfully vaccinated. For these two
respective host types, we define the lifetime transmission potential
as Lvac~~ b bc
.
(mz~ a a) and Lunvac~bc=(mza). Note that Lunvac is
identical to the basic reproductive number.
If successful vaccination leads to a greater factor reduction
in infectiousness than factor increase in life expectancy
b
.
~ b bw(mza)=(mz~ a a)Þ
 
, Lvac would be lower than Lunvac and
vaccination would lead to a reduction in the proportion of people
infected (Figure 2B, circles) [34,35]. By contrast, if the factor
reduction in infectiousness is less than the factor increase in life
expectancy (b
.
~ b bv(mza)=(mz~ a a)), in the long term vaccination
would increase the proportion of people infected (Figure 2B,
triangles).
It is noteworthy that there exists an upper bound on the extent
to which a CTL-based vaccine could increase infection prevalence
in the population because the average life expectancy of
successfully vaccinated hosts would not exceed that of uninfected
hosts (1=(mz~ a a)ƒ1=m) and successfully vaccinated hosts are
unlikely to be more infectious than unvaccinated hosts (~ b bƒb).
This means that Lvac cannot exceed bc=m – i.e. the factor increase
in Lvac compared to that of Lunvac can be no more than (mza)=m.
It follows that any vaccine that reduces infectiousness by a factor of
at least (mza)=m would reduce infection prevalence. As an
example, in sub-Saharan Africa where the average life expectancy
of uninfected hosts is approximately 50 years [36] and the average
life expectancy of untreated infected hosts is approximately 10
years [37], a vaccine that reduces infectiousness by a factor of 5
(~50=10) or more would be sure to reduce the prevalence of
infection. A vaccine that does not fully restore life expectancy to
pre-infection levels could reduce infection prevalence with a lower
factor reduction in infectiousness.
Whilst it is not possible to precisely predict the way in which
vaccination would affect the lifetime transmission potential, the
way in which this metric varies across different individuals with
natural infection provides us with some clues. It is now clear that
plasma viral load is a predictor of both transmission probability
[33,38–42] and the life expectancy of untreated hosts [33,43–45].
A review of these data presented in Fraser et al. [33] suggest that
with each tenfold increase in viral load, transmission probability
per contact increases approximately linearly and life expectancy
decreases approximately linearly. The authors also explored the
combined effect of viral load and life expectancy on lifetime
transmission potential at different viral loads. Their analysis
suggests that lifetime transmission potential is greatest at a viral
load of 4.5 log10 copies per millilitre. This happens to equal the
global median set point plasma viral load [44] implying that,
averaged across a population, a vaccine that reduces the average
viral load will be sure to reduce lifetime transmission potential and
thus reduce both the prevalence of infection and uncontrolled
infection in the population.
The precise reduction in lifetime transmission potential that can
be expected from vaccination, however, remains unclear. At the
lowest dose for which estimates were available (3 log10 copies per
millilitre) Fraser et al. [33] predicted that lifetime transmission
potential would be reduced by a factor of five compared to its
maximum at 4.5 log10 copies/ml. It is hoped, however, that
vaccination can reduce viral loads to lower values than this and
ideally below the standard detection level of 50 copies/ml. This
level of viral suppression has been observed in macaques
successfully vaccinated with a CTL-based SIV vaccine [12] and
elite controllers [46,47] – individuals who successfully control
natural HIV and exhibit normal life expectancies in the absence of
drugs. Whilst data on the lifetime transmission potential of elite
controllers is limited, data from a recent antiretroviral drug trial
[48] suggest that treatment (which typically reduces viral loads
below 50 copies/ml) can reduce the likelihood of transmission
probability by at least a factor of 25 (~ b b~ c c~bc=25). If successful
vaccination could restore life expectancy to uninfected levels
(~ a a~0), this would also result in a fivefold reduction in lifetime
transmission potential. In the reminder of our simulations we have
therefore used these parameters (~ b b~ c c~bc=25 and ~ a a~0 years
21), to
assume a fivefold factor reduction in lifetime transmission
potential. In Figure 2, this best estimate is represented by the
circles. However, it is noteworthy that whilst the reductions
presented here are rather modest, a vaccine that contains many
Table 3. Additional terms referred to in the text.
Symbol Description
F The set of pairs (h,v) which have (hi,vi)~(1,0) for at least one epitope i, then a vaccinated host of type h who has virus type v, such that (h,v) [ F,i s
successfully vaccinated, i.e. they restrict at least one epitope they are vaccinated against and that epitope has no escape mutations. By contrast, a
vaccinated host with (h,v) 6[F is unsuccessfully vaccinated and has the same properties as an unvaccinated infected host.
ei The unit vector of length n that has ith coordinate equal to 1, e.g. e2~(0,1,0,0,:::0)
~ a ah
v ~ a ah
v~
~ a a if (h,v) [ F,i :e: for sucessfully vaccinated hosts
a if (h,v) 6[F,i :e: for unvacinated hosts
 




R0 The basic reproductive number. The expected number of secondary cases caused by one primary case in a wholly susceptible population. In this model
framework R0~bc=(mza).
RC The control reproductive number. The expected number of secondary cases caused by one primary case in a wholly uninfected population under a
control strategy.
Lvac Lifetime transmission potential of a successfully vaccinated host. In this model framework Lvac~~ b bc
.
(mz~ a a).
Lunvac Lifetime transmission potential of an unvaccinated or unsuccessfully vaccinated host. Lunvac~R0~bc=(mza).
K The next generation matrix
doi:10.1371/journal.pcbi.1002289.t003
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impact.
How would selection, reversion and transmission of CTL
escape mutants affect the impact of a vaccine?
Our model simulations show that CTL escape could have a
considerable effect on the impact of a vaccine. Not only would it
affect the individuals in whom the mutants are selected, but it
could also affect the impact of the vaccine at the population level.
Our model assumes that vaccinated hosts who lose viral control
due to escape revert to normal infectiousness, hence transmit
infection to others as though they had not been vaccinated.
Furthermore they transmit viral strains that carry vaccine escape
mutants, leading to an increase in the prevalence of escape
mutants at the population level.
The rate at which escape mutants are selected will therefore be
crucial to the impact of a vaccine. If escape mutants abolish
effective CTL responses, the more rapidly escape mutants are
selected, the more prevalent they would become in the population
(Figure 3C) and the less impact the vaccine would have on the
prevalence of uncontrolled infection (Figure 3A) and infection
(Figure 3B) in the population. In the absence of escape, or if escape
is very slow indeed, the reduction in infectiousness conferred by
the vaccine could be sufficient to lead to eradication of HIV
(Figure 3B, squares). These dynamics are explored for different
escape rates: fast escape (wi~~ w wi~1=3 years
21 for i=1:5), slow
escape (wi~~ w wi~1=30 years
21 for i=1:5) and no escape
(wi~~ w wi~0 years
21 for i=1:5) at each epitope.
The results presented throughout assume that at each epitope
escape occurs at the same rate in vaccinated hosts as in
unvaccinated hosts (wi~~ w wi for i=1:5). However we note that this
assumption is largely speculative. It is possible that escape could
occur more slowly or more rapidly under vaccination. One
hypothesis suggests that because vaccine induced responses will be
more effective than natural responses they will impose a greater
selective pressure on the virus and drive escape more rapidly.
Evidence for this comes from studies in which inferred escape
mutants were associated with lower viral loads [49,50] and the
presence of protective HLA class I alleles [51,52]. Rapid escape
has also been observed in some vaccinated macaques that were
experimentally infected with a pathogenic hybrid simian-human
immunodeficiency virus (SHIV) [19]. An alternative theory
suggests that early potent immune responses could curtail viral
replication to such low levels that de novo generation of escape
mutants will be restricted and thus will emerge at a slower rate
than observed under natural infection. The reduced emergence of
drug resistance with combination antiretroviral therapy compared
to single therapy [53] and with high drug adherence compared to
low adherence [54,55] provides support for this hypothesis.
Escape rates under vaccination could therefore plausibly take a
range of speeds from very rapid to not at all and could be coupled
or uncoupled to the rates observed under natural infection. This
does not qualitatively change our finding that vaccine impact will
be lower when escape mutants are more prevalent. Vaccine
impact is a decreasing function of both the rate of escape in
vaccinated hosts (wi) and the rate of escape in unvaccinated hosts
(~ w wi). However, it could dramatically change our quantitative
findings. This is demonstrated in Figure S2 in which we assume
that escape rates in vaccinated hosts are proportional to those in
unvaccinated hosts (~ w wi~kwi for i=1:5) but vary the scaling factor
(k=1/100, 1/10, 1, 10). If escape were markedly slower in
vaccinated compared to unvaccinated hosts, escape prevalence
could be much lower and vaccine impact could be much greater. If
escape were faster, vaccine impact could be reduced compared to
our original estimates.
Escape rates could also be influenced by the breadth of the
functional immune response. For example, if escape rates are
linked to viral replication rates, a broader CTL response could
lead to slower escape rates. This is akin to escape occurring more
slowly in hosts receiving combination antiretroviral therapy
compared to single therapy [53]. Whilst we have not modelled
this possibility, it is clear that it would also affect our quantitative
results. As vaccine breadth is increased, the population prevalence
of escape would be reduced and the impact of the vaccine would
be increased.
The fitness costs that escape mutants impose on the virus will
also affect the impact of a vaccine. Fitness costs can lead to
reversion of escape mutants following transmission to HLA
mismatched hosts. If escape mutants are stable they would
continuously accumulate in the population until fixation (yi~0
years
21 for i=1:5; Figure 4C, squares), eventually rendering a
vaccine useless for future generations (Figure 4A and 4B, squares).
However, this could take several decades. If instead, escape
mutants revert in HLA-mismatched hosts they would not increase
indefinitely, but would reach a prevalence that is determined by
the rate of selection and reversion of escape mutants (Figure 4C
and Figure 5). The escape prevalence would be lower if reversion
is faster. A vaccine would therefore have more impact in reducing
the prevalence of uncontrolled infection (Figure 4A) and infection
(Figure 4B) in the population if escape mutants confer a greater
fitness cost to the virus and revert more rapidly in HLA
mismatched hosts.
Taken alone the inferences from our analysis suggest that
regions of the HIV genome that remain more conserved (i.e.
escape slowly and revert quickly) under natural immune responses
would make the best targets for a vaccine. However, it is important
to highlight that moderating the effects of CTL escape is not the
only consideration for a vaccine. The targeted genomic region
must also be able to elicit potent immune responses in the first
instance. It is not a given that regions that are most robust to
escape are also the most potent. For example pol is the most
conserved of the HIV genes and yet pol-specific responses did not
emerge as statistically associated with lowering viremia in a recent
study [32]. In that study, only gag-specific responses displayed
Figure 1. A schematic form of the single epitope version (n=1) of the mathematical model of within-host evolution and between-
host transmission of escape mutants in a vaccinated population. In this model between-host transmission is modelled using a standard
mathematical description of the frequency-dependent transmission of an infectious disease from which there is no recovery [29]. However, it includes
extra stages of compartmentalisation representing whether the hosts are 1) HLA matched or mismatched for the epitope; 2) susceptible vaccinated,
resistant vaccinated or unvaccinated and 3) whether the infected hosts have the wildtpe (WT) or the escape mutant (EM) strain. There are two
additional processes: escape in HLA matched hosts infected with the wildtype strain and reversion in HLA mismatched hosts infected with the
mutant strain. Escape occurs at rate ~ w w in vaccinated hosts and rate w in unvaccinated hosts. Reversion occurs at rate y in both host types. Infected
vaccinated hosts who are HLA matched for the vaccine epitope and who do not have an escape mutant at that epitope have a longer life expectancy
compared to other infected hosts (1=(mz~ a a)w1=(mza)). Such individuals are also less infectious so make a smaller per capita contribution to the
force of infection (~ b bvb). Thus the force of infection for wildtype virus is defined as l0~ bc(Y1
0zY0
0z~ Y Y0
0)z~ b b~ c c~ Y Y1
0
   .
N and for escape mutant virus





    
N.
doi:10.1371/journal.pcbi.1002289.g001
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that epitopes with the highest prevalence of inferred escape
mutants are mostly restricted by HLA alleles that confer a survival
advantage. This suggests that the best regions of the genome for
eliciting responses under vaccination may actually be those that
elicit natural responses that are strong enough to drive CTL
escape and hence are less conserved than other regions. The best
regions for a vaccine would therefore be the ones that balance
the need to elicit effective responses with the detrimental effect of
CTL escape.
Should a vaccine span a broad or narrow range of CTL
epitopes?
We have investigated how the impact of a vaccine could be
affected by the number of epitopes to which the vaccine elicits
responses. Using this model we predict that a vaccine would be
more effective if it elicits responses to a larger number of epitopes.
Because each epitope is recognised by only a fraction of all hosts,
the more epitopes included in the vaccine, the larger the average
number of vaccine-elicited responses per host. It is plausible that
protection offered by multiple epitopes is additive, so hosts who
recognise several epitopes could control virus better than hosts
who recognise a single epitope. Our model, however, assumes that
a host’s viral control is the same regardless of whether a single
epitope or multiple epitopes are recognised. Even under this more
conservative ‘all or nothing’ assumption, a vaccine that elicits more
responses would be more effective in reducing uncontrolled
infections (Figure 6A). More epitopes means that more hosts
recognise at least one epitopes, so have some protection, and that
more hosts remain protected by alternative responses if escape
occurs in one of the epitopes they restrict. The benefits associated
with a broader response are seen despite relative invariance with
vaccine breadth in the escape prevalence amongst HLA-matched
hosts at each epitope (Figure 6C). Two conflicting forces that result
from the increase in protection offered by additional epitopes
affect the prevalence of escape. Broader protection means that
hosts live longer so have more time to select escape mutants in any
particular epitope. However, this is outweighed by the fact that
broader protection also means that infectiousness is reduced and
escape mutants are transmitted onto other hosts less frequently.
Infection prevalence reduces only to a small extent with increased
vaccine breadth (Figure 6B).
It is important to highlight that these results assume that
epitopes act independently. One component of this assumption is
that escape rates at each epitope are independent of the presense
of escape mutants at other epitopes and are therefore independent
of the contribution that other epitopes make to viral control. As
mentioned previously, if escape rates were linked to viral
replication rates, a broader vaccine could lead to slower escape
rates. This could markedly reduce the escape prevalence at each
epitope and improve the impact of the vaccine compared to the
simulations presented here.
Figure 2. The impact of a CTL-based vaccine is dependent
upon the extent to which it affects transmission potential. This
figure considers the impact that a five-epitope vaccine could have on
an epidemic. Two measurements are considered: A) the proportion of
hosts in the population with uncontrolled infections and B) the
proportion of hosts who are infected. In each panel two vaccines with
different average transmission potentials are explored and compared to
the scenario when the vaccine is absent (black line). Our simulations are
based upon an epidemic in a sub-saharan community, thus we assume
a basic reproductive number of 2 in the absence of vaccination
(R0~Lunvac~2,bc~0:2,mza~1=10years
21). One vaccine (circles, A and
B) considerably reduces transmission probability by a factor of 25
(~ b bc~0:008), but restores life expectancy to its normal value (50 years;
mz~ a a~1=50 years
21). This vaccine reduces transmission potential by a
factor of 5 (from Lunvac~2 to Lvac~0:4). The second example vaccine
(triangles, A and B) causes a modest two fold reduction in transmission
probability (~ b bc~0:1) and restores life expectancy to the its uninfected
value (mz~ a a~1=50). Thus, this vaccine more than doubles the
transmission potential (Lvac~5). In both cases the vaccine is
administered to all unvaccinated hosts 50 years into the epidemic
and to all newborns (c=1) thereafter, but provides no level of sterilizing
immunity (r=0). This figure shows that a vaccine that reduces the
transmission potential (LvacvLunvac) – i.e. suppresses infectiousness by
a greater factor than it increases life expectancy – would reduce both
the proportion of hosts with uncontrolled HIV (circles, A) and the
proportion of hosts infected with HIV (circles, B). A vaccine that reduces
transmission potential (LvacwLunvac) would also decrease the propor-
tion of hosts with uncontrolled HIV (triangles, A), but would marginally
increase the proportion of hosts infected with HIV (triangles, B). For
these figures we assume that the vaccine elicits responses to five CTL
epitopes. At each epitope escape in HLA matched hosts escape takes an
average 8 years following infection (wi~~ w wi~1=8 years
21 for i=1:5).
Reversion in HLA mismatched hosts takes an average of 36 years at
each epitope (yi~1=36 years
21 for i=1:5). We also assume that at the
start of the epidemic 0.1% of the population are infected and that all of
these hosts are infected with the wildytype strain.
doi:10.1371/journal.pcbi.1002289.g002
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responses are not in competition with each other. Each response is
either beneficial or neutral to viral control. Our assumption that
epitopes do not compete is based upon results from a large study of
competition between CTL responses [56]. However, if epitopes
do compete and some responses are more effective than others,
then increasing the breadth of a vaccine could potentially be
detrimental to the impact of a vaccine.
Should a vaccine target epitopes restricted by rare or
common HLA alleles?
Whilst we have demonstrated that in theory a vaccine should
elicit as broad a response as possible, engineering limitations could
restrict breadth in practise. In such case, it is pertinent to ask
whether it is preferable to target epitopes that will be recognised by
a small or large fraction of the population. In other words, should
a vaccine target epitopes restricted by rare or common HLA types.
This question is non-trivial because an epitope restricted by
a common HLA will span a larger fraction of the population,
but will also accrue escape mutants more rapidly. We explore
this question in Figure 7, where the dynamics of three vaccines,
targeting differentially prevalent HLAs, are explored. One exam-
ple vaccine elicits responses to five epitopes, each recognised by
10% of the population (circles). In the remaining two examples,
each epitope is recognised by 30% (triangles) and 50% (squares) of
the population, respectively. Figure 7C indicates that, all else being
equal, the prevalence of escape at each epitope amongst HLA
matched hosts increases as the HLA prevalence increases. This
ensures that the impact of the vaccine does not continuously
increase with HLA prevalence. As HLA prevalence initially
increases, impact improves because of greater coverage (Figures 7A
and 7B; the 30% vaccine (triangles) is more effective than the 10%
vaccine (circles)); however, as prevalence increases further, the
detrimental effects of escape eventually outweigh the increase in
coverage (Figures 7A and 7B; the 50% vaccine (squares) is less
effective than the 30% vaccine (triangles)). This result is
demonstrated more explicitly in Figure 7D in which the
proportion of hosts with uncontrolled infection 200 years into an
epidemic after vaccination (50 years into an epidemic) with a single
Figure 3. The impact of a vaccine will be greater if the rate at
which immune escape mutants emerge is slower. This figure
explores how the rate at which immune escape mutants emerge in HLA
matched hosts affects the impact of a five-epitope vaccine delivered to
the all hosts in the population (c~1) 50 years into an epidemic. Three
different escape rates are considered: rapid escape (circles wi~~ w wi~1=3
years
21 for i=1:5), slow escape (triangles; wi~~ w wi~1=30 years
21 for
i=1:5) and no escape (squares; wi~~ w wi~0 years
21 for i=1:5) at each
epitope. In each example, escape occurs at the same rate in vaccinated
and unvaccinated hosts (wi~~ w wi for i=1:5). Reversion takes an average
of 36 years at each epitope in both vaccinated an unvaccinated hosts
(yi~1=36 years
21 for i=1:5). A) shows the proportion of hosts with
uncontrolled HIV. B) shows the proportion of hosts infected with HIV.
C) shows the escape prevalence amongst HLA-matched hosts. The
impact of vaccination (red lines) is compared to the scenario where
vaccination is absent (black lines). This figure shows that the prevalence
of escape amongst HLA-matched hosts at each epitope would be lower
(C) and the vaccine would be more effective in reducing the prevalence
of uncontrolled HIV (A) and HIV infection (B) if the rate of escape were
slower. The assumptions and parameters used in these figures are the
same as those described for Figure 2 except that the infectiousness and
life expectancy of successfully vaccinated hosts are fixed at ~ b bc~0:008
and mz~ a a~1=50, respectively (Lvac~0:4). Note that in this figure and
the remaining figures, different markers (e.g. circles, triangles and
squares) are used to distinguish between different model outputs.
These do not represent data.
doi:10.1371/journal.pcbi.1002289.g003
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restricting HLA at that epitope. Thus, an intermediate HLA
prevalence optimises vaccine impact. For example, for an epitope
that escapes at a rate of 1/8 years
21 and reverts at rate of 36
years
21, a restricting HLA prevalence of 32% will optimise
vaccine impact (Figure 7D).
Optimal HLA prevalence is not the same for all epitopes,
though. It is higher if reversion is slower and it varies with the rate
of escape (Figure 7E). Furthermore, it can also be affected by the
nature of the other epitopes that are present in the vaccine (i.e.
their escape rates, reversion rates and restricting HLA preva-
lences). In the context of our simple model – which assumes that
epitopes act independently – the effect of other epitopes upon
the optimal HLA prevalence at any particular epitope is small
(Figure S3). However, it is clear that if the impact of different
epitopes upon viral control is heavily interdependent, such as in
the presence of competition between CTLs, the optimal HLA
prevalence for any particular epitope could be greatly influenced
by the nature of the other epitopes in the vaccine. As an example,
consider an epitope which elicits a CTL response that contributes
nothing or very little to viral control and yet competes strongly
with effective CTLs directed against other epitopes. The optimal
HLA prevalence would be very low, irrespective of the rate at
which escape and reversion occur in that epitope.
In summary, epitopes that optimise vaccine impact tend to
escape slowly, revert quickly and are restricted by intermediately
prevalent HLAs. However it is the combination of each of these
factors and the nature of interdependence between epitopes that
determines which epitopes will be optimal.
The control reproductive number
To investigate the impact of a vaccine on an HIV epidemic
theoretically and to confirm our numeric interpretation of the
model, we have determined the control reproductive number (RC)
for the one-epitope (n~1) version of this system (Text S2 and
Figure 1). The term RC is analogous to the basic reproductive
number (R0) – the expected number of secondary cases caused by
one primary case in a wholly susceptible population – but it
accounts for a portion of the population being resistant to infection
because of a control strategy, in this case vaccination. Thus RC
can be regarded as the expected number of secondary cases caused
by one primary case in a wholly uninfected population under a
Figure 4. The impact of a vaccine will be greater if the rate at
which immune escape mutants revert in HLA mismatched
hosts is faster. This figure explores how the rate at which immune
escape mutants revert in HLA mismatched hosts affects the impact of a
five-epitope vaccine delivered to the population 50 years into an
epidemic. Model simulations are presented for different reversion rates:
rapid reversion (circles; yi~1=3 years
21 for i=1:5), slow reversion
(triangles; yi~1=30 years
21 for i=1:5) and no reversion (squares; yi~0
years
21 for i=1:5) at each epitope in both vaccinated and unvaccinated
hosts. Escape takes an average of 8 years at each epitope in both
vaccinated an unvaccinated hosts (wi~~ w wi~1=8 years
21 for i=1:5). A)
shows the proportion of hosts with uncontrolled HIV. B) shows the
proportion of hosts infected with HIV. C) shows the escape prevalence
amongst HLA-matched hosts. The impact of vaccination (red lines) is
compared to the scenario where vaccination is absent (black lines). This
figure shows that the prevalence of escape amongst HLA-matched
hosts at each epitope would be lower (C) and the vaccine would be
more effective in reducing the prevalence of uncontrolled HIV (A) and
HIV infection (B) if immune escape mutants revert more rapidly in HLA
mismatched hosts. The assumptions and parameters used in these
figures are the same as those described for Figure 2 except that the
infectiousness and life expectancy of successfully vaccinated hosts are
fixed at ~ b bc~0:008 and mz~ a a~1=50, respectively (Lvac~0:4).
doi:10.1371/journal.pcbi.1002289.g004
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R0~Lunvac, RC is not equal to Lvac. Whereas Lvac describes the
lifetime transmission potential of a specific host type (vaccinated
hosts), RC describes the average lifetime transmission potential of
an average individual in a population – some of whom are
vaccinated and some of whom are not. In the simulations
presented here we have assumed that vaccination does not confer
any level of sterilizing immunity (r~0). However, for complete-
ness, for the analysis of the control reproductive number, we use
the more general version of our model in which a fraction (r§0)o f
vaccinated hosts wholly are resistant to infection.
In a system that has only one infection state, the expected number
of secondary cases from one primary case has a simple meaning since
there is only one type of primary case and one type of secondary case.
In the single-epitope version of our model, however, there are eight
different infection states and the expected number of secondary cases
from one primary case is dependent upon the state of the primary
case. Thus RC can be defined more precisely to be the expected
number of secondary cases produced by a typical individual in a wholly
uninfected population, where by ‘typical’ we mean an individual
whose state is distributed according to the average distribution of hosts
amongst the different states. Another way of phrasing this is that is that
RC is the average per-generation multiplication number [57].
Under this definition, RC can be found by calculating the largest
eigenvalue of the next generation matrix, K, where the elements of
K, klm, are the average number of individuals of infectious state l,
created when a single individual of state m is introduced into the
population [57]. In our model there are eight infectious states,
however the model can be collapsed into a minimum of five states.
Y1
1 and ~ Y Y1
1 can be combined intoa single state,   Y Y1
1 (Y1
1z~ Y Y1
1~  Y Y1
1),
which represents infected HLA-matched hosts with escape,
and similarly for the pairs Y0
0 and ~ Y Y0
0, and Y0
1 and ~ Y Y0
1. The
next generation matrix of the five states Y1
0, ~ Y Y1
0,   Y Y1
1,   Y Y0
0,   Y Y0
1 is
provided in Text S3.
The analytic formula for the largest eigenvalue of this matrix,
although it can be written out explicitly, is too complex to yield
insight so is not presented. However, the control reproductive
number (RC) for this system can be calculated numerically for
specific parameter values. Some example values are given in Text
S4. These examples confirm the dynamic model outputs. They
show that a CTL-based vaccine would have more impact upon an
epidemic – i.e. RC would be lower – if escape in vaccinated (~ w w1)
and unvaccinated (w1) HLA matched hosts is slower, reversion in
HLA mismatched hosts (y1) is faster, the transmission coefficient
of successfully vaccinated hosts (~ b bc) is lower, the life expectancy of
successfully vaccinated hosts (1=(mz~ a a)) is shorter, the proportion
of hosts who are vaccinated (c) is higher and the fraction of
vaccinated hosts resistant to infection is greater (r). Furthermore,
RC a u-shaped function of HLA prevalence (p
1) and RC is lower if
for unvaccinated (or unsuccessfully vaccinated) hosts the trans-
mission coefficient (bc) is smaller or the life expectancy (1=(mza))
is shorter. Finally, assuming that the life expectancy of infected
hosts is fixed (i.e. 1=(mza) and 1=(mz~ a a) are both fixed), RC is
invariant to the life expectancy of uninfected hosts (1=m).
Discussion
We have explored the impact of a CTL-inducing vaccine that
reduces infectiousness and extends life expectancy upon the
prevalence of infection and uncontrolled infection in the
population. Specifically, we have explored how the impact of
such a vaccine would be affected by the spread of escape mutants,
the breadth of the induced CTL response and the fraction of the
population that recognises each epitope in the vaccine.
Firstly, our model has shown that vaccination could reduce the
prevalence of uncontrolled infection and could also reduce the
prevalence of infection by reducing the infectiousness of infected
Figure 5. Contour plots showing how the prevalence of escape
amongst A) HLA matched hosts and B) all hosts varies according
to the escape and reversion rate. These contour plots explore how the
prevalence of escape 200 years into an epidemic varies according to the rate
of escape in HLA matched hosts and the rate of reversion in HLA
mismatched hosts. Vaccination is applied to all hosts in the population 50
years into an epidemic. Escape is assumed to occur at the same rate at each
epitope. Reversion is assumed to occur at the same rate at each epitope and
revert at the same rate. At each epitope, escape rates in vaccinated and
unvaccinated HLA-matched hosts are assumed to be equal (wi~~ w wi for
i=1:5). The escape and reversion rates are presented in terms their
r e c i p r o c a l–t h ea v e r a g et i m et oe s c a p e( x-axis) and average time to
reversion (y-axis). The contours show that the prevalence of escape amongst
A) HLA-matched hosts and B) all hosts increases as the rate of escape
increases and the rate of reversion decreases; however, the increase in
escape prevalence in HLA-matched hosts with reversion rate is limited when
revision takes an average of 10 years or less. The assumptions and
parametersusedinthesefiguresarethesameasthosedescribedforFigure2
except that the infectiousness and life expectancy of successfully vaccinated
hosts are fixed at ~ b bc~0:008 and mz~ a a~1=50, respectively (Lvac~0:4).
doi:10.1371/journal.pcbi.1002289.g005
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prevalence, however, is dependent not only upon the extent to
which it reduces infectiousness, but also the extent to which it
extends life expectancy and thus extends the period over which
transmission can occur. A CTL inducing vaccine could actually
increase infection prevalence if the reduction in infectiousness is
more than outweighed by the increase in longevity, but any
increase is likely to be marginal. Furthermore data from natural
infection concerning the relationship between infectiousness, life
expectancy and viral set point suggests that vaccination is most
likely to reduce overall transmission potential by a factor of at least
five and therefore reduce infection prevalence.
Secondly, our model has shown that the impact of a CTL-
inducing vaccine could be significantly reduced by CTL escape,
particularly if escape is rapid and mutants confer low fitness costs,
so revert only slowly in HLA mismatched hosts. The model
therefore suggests that a vaccine would be more robust to escape if
it spans a conserved, functional region of the genome. It is
important to acknowledge, however, first and foremost, that a
vaccine must be able to elicit effective immune responses. The
most conserved regions of the genome are not necessarily able to
induce the most effective responses. For example pol is the most
conserved of the HIV genes and yet in recent study pol-specific
responses were not associated with lowering viremia [32]. The best
vaccine would therefore be one which weighs up the need to elicit
effective responses with the detrimental effect of CTL escape.
Thirdly, our model has shown that in the absence of
competition between CTL responses, a vaccine would be more
effective if it spans a broader range of CTL epitopes. Such a
vaccine would provide protection for a larger proportion of hosts
and would also be more robust to the effects of CTL escape.
Finally, we have shown that the frequency with which each
epitope is recognised in the population will affect vaccine impact.
An epitope restricted by a prevalent HLA will span a greater
fraction of the population, but will also accumulate escape mutants
more rapidly. Thus epitopes restricted by an intermediate fraction
Figure 6. The impact of a vaccine would increase with vaccine
breadth. This figure explores how breadth of a vaccine would affect its
impact when delivered to a population 50 years into an epidemic.
Model simulations are presented for vaccines that elicit responses to
one epitope (circles), three epitopes (triangles) and 5 epitopes (squares).
Escape takes an average of 8 years at each epitope in both vaccinated
an unvaccinated hosts (wi~~ w wi~1=8 years
21 for i=1:5). Reversion takes
an average of 36 years at each epitope in both vaccinated an
unvaccinated hosts (yi~1=36 years
21 for i=1:5). A) shows the
proportion of hosts with uncontrolled HIV. B) shows the proportion
of hosts infected with HIV. C) shows the escape prevalence amongst
HLA-matched hosts. The impact of vaccination (red lines) is compared
to the scenario where vaccination is absent (black lines). C) shows that
the prevalence of escape at each epitope in HLA-matched hosts would
be relatively invariant to the number of epitopes included in the
vaccine. Two conflicting forces that result from the increase in
protection offered by additional epitopes affect this prevalence. More
protection means that hosts live longer so have more time to select
escape mutants, but also means that hosts are less infectious, so are less
likely to transmit mutants to other hosts. Despite the lack of variation of
escape prevalence (at each epitope) with vaccine breadth, vaccines that
elicit broader responses would be markedly more effective at reducing
disease (A) because they would ensure that more hosts have the
potential to recognise at least one epitope and more hosts remain
protected by alternative responses if escape occurs in one epitope.
Infection prevalence would also reduce with increased vaccine breadth
(B), but to a lesser extent. The assumptions and parameters used in
these figures are the same as those described for Figure 2, except that
the infectiousness and life expectancy of successfully vaccinated hosts
are fixed at ~ b bc~0:008 and mz~ a a~1=50, respectively (Lvac~0:4).
doi:10.1371/journal.pcbi.1002289.g006
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precise restricting HLA prevalence for any epitope that optimises
vaccine impact is dependent upon the rate at which mutants
escape and revert at that epitope, as well as the nature of other
epitopes included in the vaccine. In a scenario where vaccine
breadth is limited, the choice of which epitopes to include in the
vaccine should therefore account for the combined effects of
escape rates, reversion rates and restricting HLA prevalences of
different epitopes.
Wehavedeliberatelykeptour modelsimpletoallow a transparent
explanation of what assumptions we have made. However, it is not
difficult to propose ways in which the emergence of escape mutants
in a vaccinated population is more complicated than is represented
by our model. One of the mainassumptions made inour simulations
is that the vaccine does not provide any level of sterilizing immunity
(r~0). Following the partial success of the Thai vaccine trial in
which HIV incidence was reduced by 31% over the first three years
following inoculation [15], it has become less likely that an HIV
vaccine with no ability to prevent infection will be made widely
available. Although the primary concern of our study was a non
sterilizing CTLbasedvaccine,ourmodelisalsodesignedtoallowfor
a fraction, r, of vaccinated hosts to be completely resistant to
infection. In the results discussed throughout this paper we have
assumed that r~0. However, as demonstrated by our analysis of the
control reproductive number (Text S4), infection prevalence would
decreases as the fraction of vaccinated hosts resistant to infection (r)
increases. Indeed, irrespective of CTL escape and reversion rates, a
vaccine with a neutralising component could lead to eradication of
HIV if the fraction of hosts resistant is sufficiently large.
Our model also makes many simplifying assumptions about the
way in which escape mutants evolve within individuals and transmit
between individuals. For example, we assume that escape mutants
c a n n o tr e v e r ti nH L Am a t c h e dh o s t s ;t h a te s c a p ea n dr e v e r s i o nr a t e s
are homogeneous across the duration of infection; that people are
equally infectious throughout their infection and that epitopes are
independent entities which do not overlap each other. We have
previously explored the impact of these assumptions on the spread of
escape mutants in an unvaccinated population [22]. We have shown
that such factors could change the pace of the spread of escape
mutants in the population, but would not qualitatively change our
findings. Likewise, in the context of a vaccinated population, as
studied here, our main findings are robust to these assumptions. We
have also assumed that individuals are infectious with only one viral
strain at a time. In reality, individuals harbour a quasispecies of viral
strains, yet transmit single or very few virions during each
transmission event [58,59], thus it is not certain that the dominant
strain within the transmitter will be passed to the recipient. It is
possible that escape mutants could, on average, be transmitted less
frequently than predicted by the single strain model. However, this
too does not affect our main findings that vaccine impact will be
greater if mutants escape slowly, revert quickly and the breadth of the
response is greater. Numerically, a reduction in the transmission
probability of escape mutants will have a similar effect to an increase
in reversion rate.
Other simplifications pertain to the description of the vaccine. For
example, we have run our model simulations using a vaccine that
contains up to five CTL epitopes. Ideally a vaccine would make
responses to more epitopes than just five. In addition, the fraction of
the population that respond to most epitopes in a vaccine is likely to
be less than the 20% we have assumed in our simulations. The
spread of escape at any particular epitope is therefore likely to be a
little more sedate than we predict. Furthermore, the number of
epitopesthatan averageindividualwillmakea responsetoislikelyto
be much more than the median of just one that our simulations
assume. This, combined with a reduction in the spread of escape
mutants, could lead to a more effective and robust vaccine than we
predict.Indeed,theextenttowhichavaccineremainseffectiveinthe
face of escape is another assumption that we have made. We have
assumed that the vaccine willconfer protection inallindividuals who
restrict at least one epitope they are vaccinated against and in which
escape mutations are absent. In reality, the level of protection from a
vaccine could change in a more progressive manner, i.e. could
increase steadily with the number of epitopes providing protection.
We would expect that such processes would change our results
quantitatively, but not qualitatively.
One assumption that affects our qualitative as well as our
quantitative results is that epitopes act independently. Thus, we
assume that different epitope-specific immune responses are not in
competition with each other. Each response is either beneficial or
neutral to viral control. This assumption has important implica-
tions because if epitopes do compete and some responses are more
effective than others, then increasing the breadth of a vaccine
could potentially be detrimental to the impact of a vaccine. Our
assumption is based upon results from a large study of competition
between CTL responses [56]. Contrary to smaller studies that
focussed on a limited number of individuals and/or a limited
number of epitopes [60–61], this study found no evidence for
competition between CTL responses directed against different
HIV-1 epitopes. However, we note that there is scope to
investigate evidence for competition further with different patient
cohorts and more detailed CTL response measurements. In
particular, it would be interesting to investigate competition data
from post-infection vaccine trials, as this would closely match the
experimental manipulation of CTLs that is used to test for
Figure 7. The impact of a vaccine varies with the fraction of the population that are HLA-matched for each epitope. Panels A), B) and C)
explorehowthefrequencywithwhichepitopesarerecognisedinthepopulationaffectstheimpact ofafive-epitopevaccinedeliveredtothepopulation
50 years into anepidemic. Modelsimulations arepresentedunder different assumptions about the fractionof thepopulation that is HLA match foreach
of the five epitopes: 10% (circles), 30% (triangles) and 50% (squares). Escape takes an average of 8 years at each epitope in both vaccinated an
unvaccinated hosts (wi~~ w wi~1=8 years
21 for i=1:5). Reversion takes an average of 36 years at each epitope in both vaccinated an unvaccinated hosts
(yi~1=36 years
21 for i=1:5). A) shows the proportion of hosts with uncontrolled HIV. B) shows the proportion of hosts infected with HIV. C) shows the
escape prevalence amongst HLA-matched hosts. The impact of vaccination (red lines) is compared to the scenario where vaccination is absent (black
lines). C) reveals that the prevalence of escape amongst HLA-matched hosts at each epitope would be higher if the restricting HLA is more prevalent.
However, escape prevalence is not the only factor which contributes to vaccine impact since epitopes restricted by more prevalent HLAs will also
provide protection to a greater fraction of the population. A) and B) reveal that an intermediate HLA prevalence (30% in this example, triangles) can
optimise vaccine impact. This result is demonstrated more explicitly in panel D) in which the prevalence of uncontrolled infection for the single-epitope
version of the model 200 years into an epidemic is used to explore the effect of HLA prevalence upon vaccine impact . D) shows that uncontrolled
infection prevalence is a u-shaped function of the restricting HLA prevalence, thus is minimised at intermediate HLA prevalences. In this example
(w1~~ w w1~1=8 year
21 and y1~1=36 years
21) vaccine impact is optimised when 32% of the population are HLA matched for the epitope. E) shows that
theHLAprevalence that maximisesvaccineimpact200 years into anepidemicis dependent upon therate of escapein HLA matched hosts (w1~~ w w1) and
rates of reversion in HLA mismatched hosts (y1). The assumptions and parameters used in these figure are the same as those described for Figure 2,
except that the infectiousness and life expectancy of successfully vaccinated hosts are fixed at ~ b bc~0:008 and mz~ a a~1=50, respectively (Lvac~0:4).
doi:10.1371/journal.pcbi.1002289.g007
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competition between CTL responses directed against different
epitopes it would change our finding that increasing the breadth of
a vaccine is always beneficial. Instead, a vaccine with a relatively
limited breadth, focussed on particularly effective responses could
be optimal. Likewise, competition would change the dependency
of vaccine impact upon the escape rate, reversion rate and
restricting HLA prevalence for each epitope.
Our assumption that epitopes act independently also means that
the diversity of the functional CTL response has no impact upon
escape and reversion rates. The only factor we assume influences
escape rates is whether or not the individual is vaccinated.
Reversion rates are fixed across both vaccinated and unvaccinated
host. It is plausible that a more diverse CTL response could repress
viral replication to lower levels, thereby restricting the de novo
generation of escape mutants and thus reducing escape rates
compared to those observed natural infection. A sufficiently broad
vaccine could prevent escape all together. An alternative hypothesis
suggests that vaccination could increase escape rates compared to
natural infection because of a greater selective pressure imposed by
more potent responses. Precisely how quickly escape will occur
under vaccination therefore remains an open question.
Methods
The model that we have developed can be described as follows:
suppose that the vaccine induces responses to n different epitopes.
The vector h~(h1,h2,:::,hn) represents the host type, indicating
which of the n epitopes the host restricts: hi~1 if the host restricts
epitope i and hi~0 if it does not. Hosts are born into the
population at a constant rate B, thus birth rates are independent of
current host densities. In our simulations we set this parameter to
equal to the multiple of the population death rate (m) and the total
population size at the start of the simulation. Thus, the population
size would remain constant in the absence of infection. A fraction,
ph, of these newborns are of host type h, ensuring that in the
absence of vaccination, the fraction of the population with each
host type remains fixed. A fraction, c, of newborns receive the
vaccine at birth and a fraction, r, of vaccinated hosts are resistant
to infection. At any given time, t, each infected host is assumed to
be infected with a single viral strain. This strain may or may not
carry a mutation at each of the n epitopes. The vector
v~(v1,v2,:::,vn) is the virus type, indicating the epitopes at which
the virus carries escape mutants: vi~1 if the virus is mutant at
epitope i and vi~0 if it is wildtype. Rh(t), ~ X Xh(t) and Xh(t)
represent the number of vaccinated resistant, vaccinated suscep-
tible and unvaccinated susceptible hosts of type h at time t,
respectively. These hosts each have an average life expectancy of
1=m. ~ Y Yh
v (t) and Yh
v (t) represent the number of vaccinated and
unvaccinated type h hosts infected with virus type v at time t,
respectively. N(t) is the total number of hosts in the population at







v z~ Y Yh
v
     
.I fF is
the set of pairs (h,v) which have (hi,vi)~(1,0) for at least one
epitope i, then a vaccinated host of type h who has virus type v,
such that (h,v)[F, is successfully vaccinated, i.e. they restrict at
least one epitope they are vaccinated against and that epitope has
no escape mutations. By contrast, a vaccinated host with (h,v) 6[F
is unsuccessfully vaccinated and has the same properties as an
unvaccinated infected host. Text S1 demonstrates the use of this
notation in an example that considers a vaccine that contains five
epitopes. Successfully vaccinated hosts are less infectious than
unvaccinated or unsuccessfully vaccinated infected hosts (~ b bvb),
but their average life expectancy is longer (1=(mz~ a a)w1=(mza);
equivalently ~ a ava). This imposes a limited degree of selection on
host HLA genotypes over the course of an infection (e.g. in our
simulations an initial HLA prevalence of 20% increases to 21%
after 200 years) and has no significant impact upon the dynamics
that we explore. We have previously investigated the impact of
the HIV epidemic upon HLA gene frequencies amongst the
population in absence of vaccination [62]. A variation of our
vaccine model in which the birth rate of each host type is
dependent upon the current density of that host type in the
population could be used to fully explore host-pathogen co-
evolution under vaccination, but for brevity we do not explore
these dynamics here.
The average rate of partner exchange (c) is assumed to be the
same for all host types. In line with convention for a sexually
transmitting disease, this parameter is included explicitly, despite
being mathematically redundant, appearing as a scaling factor
of b and ~ b b throughout. Overall the force of infection from






















C A, that is the
weighted sum of infectiousness from the three host types infected
with virus type v: unvaccinated, unsuccessfully vaccinated and
successfully vaccinated. For hosts who recognise epitope i and who
are infected with a virus that is wildtype at epitope i, the rate of
escape at that epitope is ~ w wi if they are vaccinated and wi if they are
not. Regardless of vaccination, the rate of reversion at epitope i is
yi in hosts who don’t recognise epitope i and are infected with a
mutant at epitope i. To enable us to write the model equations in a
simple and general form we have defined ei to be the unit vector of
length n that has ith coordinate equal to 1, e.g. e2~(0,1,0,0,:::0);
dkl to be the Kronecker delta and ~ a ah
v~~ a a if (h,v)[F and ~ a ah
v~a
otherwise (Table 3). Using these, the model can be described by
the set of coupled ordinary differential equations given in
expression (1). Tables 1 and 2 summarise the variables and
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one epitope (n~1), is represented graphically in Figure 1.The
model equations for the single-epitope version of the model are
presented in Text S2.
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